Facet Life Sciences was recently featured in Life Sciences Review, spotlighting the firm’s entrepreneurial approach to FDA regulatory strategy for emerging biotechs. Life Sciences Review recently sat down with Dr. Tom Hal...
Industry & Company News
Read the latest news and announcements from Facet Life Sciences. Stay informed about our innovations and industry engagements.
Facet Life Sciences Appoints Frank A. Closurdo as VP, Commercial Services, Strengthening Integrated Regulatory and Market Guidance
Wayne, PA — June 2, 2026 — Facet Life Sciences, a product pathmaker for emerging biotechnology and pharmaceutical companies, today announced the appointment of Frank A. Closurdo as Vice President, Commercial Services. This addi...
Facet Life Sciences Evolves Leadership Structure to Strengthen Product Pathmaking Solutions & Deepen Partnership Value
Wayne, PA — May 13, 2026 — To support continued growth, Facet Life Sciences, a product pathmaker for emerging biotechnology, pharmaceutical, and device developers, today announced executive team changes. Facet helps lean scienc...
Facet’s Dana Blue Returns to AMWA Regulatory Writing Subcommittee for 2026
Shaping The Future of Regulatory Writing Education Facet Life Sciences is proud to share that Dana Blue, Strategic Program Champion and Medical Writing Team Manager, has been asked to rejoin the Regulatory Writing Subcommittee ...
Facet Life Sciences and XCancer Announce Strategic Partnership to Advance Theranostic Clinical Trials
Phoenixville, PA — Facet Life Sciences, a leader in regulatory strategy and drug development services, today announced a strategic partnership with XCancer®, a global leader in theranostic clinical research, to accelerate the d...
Facet is Proud to be a 2025 SNMMI Mars Shot Research Fund Donor
Facet Life Sciences contributed to and proudly supports the 2025 Mars Shot program, a Society of Nuclear Medicine and Molecular Imaging (SNMMI) initiative that provides funding to developers using nuclear medicine to find novel...
Facet Life Sciences Announces Partnership with Nucleus as Official Regulatory Partner
Facet Life Sciences specializes in guiding life science companies through the complex journey of drug, biologic, and medical device development and registration with the US FDA. Facet is pleased to announce the company’s role a...
Facet Life Sciences Named Regulatory Partner for Cybin’s Neuropsychiatry Therapeutics Development Pipeline
Facet Life Sciences, a leader in US regulatory strategy and product development solutions for the life sciences industry, has been named as the US regulatory partner for Cybin Inc. (“Cybin”), a late-stage breakthrough neuropsy...
Facet Life Sciences Quarterly Update Q2 – 2024
From The Corner Office Q2 2024Ken VanLuvanee, President & CEO Apologies for the delay—this past quarter, we’ve championed a large number of Sponsor-FDA meetings and have had even more informal interactions in our quest to ...
Facet By The Numbers – Q2 2024
FACET BY THE NUMBERS Total ESG submissions to FDA Apr – June 2024: Over 30! Early-Stage Development Highlights 6 formal FDA meetings, 1 investigator-initiated IND, over 25 IND amendments (e.g., new protocols/amendments, CMC up...
gET sOCIAL